Full Press Release Details
Oculus Innovative Sciences Reports Revenues
of $3.3 Million for Third Quarter of Fiscal 2014
Conference Call Begins at 4:30 p.m.
PETALUMA, Calif.--(February 13, 2014)--Oculus Innovative
Sciences, Inc. (NASDAQ: OCLS) today announced financial results for the third quarter of fiscal year 2014, ended December 31, 2013.
Total revenues were $3.3 million for the third quarter, down $247,000 as compared to $3.5 million for the same period in the prior
year. Product revenue was down $278,000, or 8%, with decreases in United States, Mexico and China, partially offset by revenue
growth in Europe, Middle East and Singapore.
"All eyes are focused on reigniting our revenue growth via
six new product introductions this year including planned upcoming launches in the scar management and oral care markets,"
said Jim Schutz, Oculus CEO. "European growth should be healthy this year in light of our recent acne, dermatology procedures and
oral care approvals, as well as expected new approvals for atopic dermatitis and scar management. Also, looking forward,
we remain confident that the Ruthigen IPO process is moving forward."
Product revenue in the United States for the three months ended
December 31, 2013, was down 19% from the same period last year, with lower sales of animal healthcare and dermatology products,
partially offset by increases in wound care and human OTC products. The company recorded revenue in the amounts of $652,000 and
$883,000 from Oculus' partner Innovacyn for the three months ended December 31, 2013 and 2012 respectively. The impact of
the weather on the sales of animal healthcare products makes it difficult to compare quarterly sales to that of the same period
Revenue in Mexico for the three months ended December 31,
2013, decreased $119,000, or 9%, when compared to the same period in the prior year as a result of the lower sales of the hydrogel
product. In the same quarter last year, sales in Mexico were higher due to the filling of the distribution pipeline as More Pharma
launched its inaugural Microcyn-based products. Also, sales that were deferred prior to the close of the More Pharma transaction
were recognized on a collection basis during the three months ended December 31, 2012. During the three months ended December 31,
2013 and 2012, $379,000 was recognized related to the amortization of upfront license fees paid by More Pharma.
Revenue in Europe and "Rest of World" for the three
months ended December 31, 2013, increased $163,000, or 47%, as compared to the same period in the prior year, with increases in
sales in Europe, Middle East and Singapore, partially offset by a decrease in China.
Oculus reported gross profit related to the company's products
of $2.1 million, or 67% of product revenues, during the three months ended December 31, 2013, compared to a gross profit of $2.5
million or 73% of product revenues, for the same period in the prior year. Licensing revenues are included in the calculation of
product revenues and gross profit for the quarters ended December 31, 2013 and 2012. Gross margins were down due to the decline
of margins in Mexico due to lower unit volume and deferred sales last year, partially offset by higher gross margins in Europe.
Total operating expenses increased by $504,000, or 16%, to $3.7
million for the three months ended December 31, 2013, as compared to the same period in the prior year. Operating expenses minus
non-cash expenses during the third quarter of fiscal 2014 were $3.2 million, up $507,000 when compared to $2.7 million for the
same period in the prior year. The increase in operating expenses minus non-cash expenses was due to higher expenses of $658,000
related to the company's subsidiary, Ruthigen, partially offset by lower U.S. operating expenses incurred by Oculus of $283,000.
Research and development expenses were $775,000 for the three months
ended December 31, 2013, up $266,000 from the same period last year, due to higher preclinical expenses of $395,000 incurred by
Ruthigen. Selling, general and administrative expense increased $238,000, or 9%, to $2.9 million during the three months ended
December 31, 2013, with expenses related to Ruthigen of $263,000.
Loss from operations minus non-cash expenses for the three months
ended December 31, 2013, increased by $860,000, to $1 million, as compared to the same period in the prior year, mostly due to
$658,000 of expenses incurred related to Ruthigen, compared to $163,000 for the same period in the prior year.
Net loss for the three months ended December 31, 2013, was $611,000,
a decrease of $1.3 million, as compared to a net loss of $1.9 million for the same period in the prior year. Stock-based compensation
charges were $448,000 and $456,000 for the quarters ended December 31, 2013, and 2012, respectively. Most of the difference between
the net loss and the loss from operations relates to a gain of $1.6 million on the sale of Oculus shares by the company's
lender, which resulted in the elimination of a $3 million debt liability to the lender.
As of December 31, 2013, Oculus had unrestricted cash and cash equivalents
of $3.4 million, compared with $7.9 million as of March 31, 2013.
Results for Nine Months Ending December 31, 2013
Total revenues were $10.8 million for the nine months ended December
31, 2013, as compared to $12.1 million for the same period in the prior year. Product revenues, including product licensing fees
received, for the nine months ended December 31, 2013, decreased $1.4 million, or 12%, to $10.1 million, as compared to $11.4 million
for the same period in the prior year, with decreases in sales in the United States, Mexico and China, partially offset by increases
in Europe, Middle East, India and Singapore.
Oculus reported gross profit related to sales of Microcyn -based
products of $6.8 million, or 68% of product revenues, for the nine months ended December 31, 2013, as compared to a gross profit
of $8.5 million, or 74% of product revenues, for the same period in the prior year. Total operating expenses minus non-cash expenses
increased $691,000, for the nine months compared to the same period in the prior year, primarily due to Ruthigen-related expenses
of $2.1 million, partially offset by lower expenses incurred in Mexico of $1 million. Operating loss minus non-cash expenses (EBITDAS)
for the nine months ended December 31, 2013, was $2.6 million, which included $2.1 million of Ruthigen expenses.
Oculus management will hold a conference call today to discuss third
quarter fiscal 2014 results and to answer questions, beginning at 4:30 p.m. ET. Individuals interested in participating in the
conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those
interested in listening to the conference call live via the Internet may do so at http://ir.oculusis.com/events.cfm. Please log
on approximately 30 minutes prior to the presentation in order to register and download the appropriate software.
A telephone replay will be available for seven days following the
conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference
code 51346784. A webcast replay will be available on the site at http://ir.oculusis.com/events.cfm for one year following the call.
About Oculus Innovative Sciences, Inc.
Oculus Innovative Science is a global healthcare company that designs,
manufactures and markets prescription and non-prescription products in 31 countries. The company's products are used to treat
patients in surgical/advanced wound management, dermatology, women's health and animal health markets; addressing the unmet
medical needs of these markets, while raising the standard of patient care and lowering overall healthcare costs. The
company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More
information can be found at www.oculusis.com
Forward-Looking Statements
Except for historical information herein, matters set forth
in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance
of Oculus Innovative Sciences, Inc. and its subsidiaries (the "Company"). These forward-looking statements are identified
by the use of words such as "anticipates," "believes," "expects," "may," "plans,"
and "will," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties
inherent in the Company's business that could cause actual results to vary, including such risks that regulatory
clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt
of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection
offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the
available market for the Company's products will not be as large as expected, the Company's products will
not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical
studies, the Company may not meet its future capital needs, the Company may not be able to obtain additional funding, as well
as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different
countries and municipalities, the uncertainties associated with an initial public offering of a separate public company, and other
risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its annual report
on Form 10-K for the year ended March 31, 2013. The Company disclaims any obligation to update these forward-looking statements,
except as required by law.
Oculus and Microcyn Technology
are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property
of their respective owners.